Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Assets (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Assets for 4 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets fell 9.86% to $6.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.7 million, a 9.86% decrease, with the full-year FY2024 number at $5.8 million, down 26.01% from a year prior.
  • Assets was $6.7 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $4.2 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $9.2 million in Q3 2023 to a low of $1.3 million in Q4 2022.
  • A 4-year average of $6.2 million and a median of $6.7 million in 2025 define the central range for Assets.
  • Peak YoY movement for Assets: surged 500.04% in 2023, then tumbled 41.2% in 2024.
  • 60 Degrees Pharmaceuticals' Assets stood at $1.3 million in 2022, then soared by 500.04% to $7.8 million in 2023, then dropped by 26.01% to $5.8 million in 2024, then increased by 16.15% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Assets are $6.7 million (Q3 2025), $4.2 million (Q2 2025), and $6.0 million (Q1 2025).